Barclays increased Insmed's price target to $237 from $231 after shares rallied for a third consecutive day, completing their best monthly gain since November despite posting the company's first quarterly loss since 2024. A crossover above the 80-day moving average has occurred 17 times over the past decade, historically signaling a 59% chance of a 5.4% one-month gain.

Insmed reported Q4 Brinsupri revenues of $144.6M, surpassing launch expectations, and reiterated guidance of $1B in sales for 2026, underpinning optimism for recurring cash flow and contribution to enterprise value.

The company's enterprise value stands near $30B, driven by Brinsupri's performance and promising pipeline assets. TPIP's differentiated once-daily dosing in PAH/PH-ILD and encouraging Phase 2b data contribute to an estimated $3B risk-adjusted net present value.

Options traders have turned overwhelmingly bullish, with a 10-day call/put volume ratio of 64.74 ranking in the top 2% of readings, while a Schaeffer's Volatility Index of 43% and a Volatility Scorecard of 83 suggest lower-priced volatility expectations despite historically higher realized volatility.